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Masaaki Uematsu, MD, PHD*
Amagasaki, Osaka, Kitakyushu, Sendai, Yokohama, Nishinomiya, Kurume, Fukuoka,
and Matsuyama, JapanObjectives This study sought to investigate factors associated with restenosis after endovascular
therapy comparing TASC (Trans-Atlantic Inter-Society Consensus) II classes A to C with class D
femoropopliteal (FP) lesions.Background It is unclear whether the determinants of restenosis for TASC II class D lesions are the
same as those for TASC II classes A to C FP lesions.
Methods We studied 2,400 limbs from1,889 consecutive patients (73 17 years of age; 31%women; 30%
critical limb ischemia)whounderwent successful endovascular therapy fordenovoFP lesions. Predictors for
restenosis in TASC II classesA toCandclassD lesionswere assessedusingaCoxproportionalhazardsmodel.
Results The 5-year primary patency rate was 50% in TASC II classes A to C and 34% in TASC II class D
lesions, respectively (p < 0.001). Overall, restenosis had a signiﬁcant interaction with sex and renal
failure (both p < 0.01). Female sex was a signiﬁcant risk factor for restenosis in TASC II class D lesions
(adjusted hazard ratio [HR]: 1.80, p < 0.001) but not TASC II classes A to C lesions (adjusted HR: 1.10,
p ¼ 0.352). Conversely, renal insufﬁciency was a signiﬁcant risk factor for restenosis in TASC II classes
A to C lesions (adjusted HR: 1.43, p < 0.001) but not TASC II class D lesions (adjusted HR: 0.79,
p ¼ 0.129). Diabetes mellitus, no stent use, chronic total occlusion, and poor below-the-knee runoff
were shared risk factors for restenosis between TASC II classes A to C and class D lesions (all p < 0.05).
Conclusions For de novo FP lesions, diabetes, no stent use, chronic total occlusion, and poor below-
the-knee runoff were shared restenosis predictors for TASC II classes A to C and class D lesions, whereas
renal failure was a predictor for TASC II classes A to C lesions and female sex for TASC II class D lesions.
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793Although 50% to 70% of patients with symptomatic
peripheral arterial disease present with femoropopliteal
(FP) lesions (1–3), the preferred revascularization strategy,
particularly endovascular therapy (EVT), remains controversial
(4). Based on recently reported mid-term outcomes of nitinol
stent use, the 2011 European Society of Cardiology guidelines
have recommended an EVT-ﬁrst strategy for TASC (Trans-
Atlantic Inter-Society Consensus) II classes A to C FP lesions
and surgical bypass for TASC II class D lesions, with EVT
indicated under certain conditions for the latter (5).See page 799
Abbreviations
and Acronyms
BTK = below the knee
CI = conﬁdence interval
CLI = critical limb ischemia
CTO = chronic total occlusion
EVT = endovascular therapy
FP = femoropopliteal
HR = hazard ratio
IVUS = intravascular
ultrasound
TASC = Trans-AtlanticWidespread use of EVT in more complex FP lesions has
been fueled by recent advances, including the newer gener-
ation of nitinol stents with associated lower stent fracture
rates and improved mid-term outcomes (6,7). Current evi-
dence indicates that for FP lesions 5 cm, mid-term
patency is better for nitinol stents than for balloon angio-
plasty (6–8), and in clinical practice, EVT is often selected
for TASC II class D lesions because of a patient’s poor
general condition (9–11).
Despite EVT’s common use, risk of restenosis in TASC II
class D lesions has not been systematically studied. It is also
unclear whether the risk of restenosis for TASC II class D
lesions is the same as those for TASC II classes A toC lesions.
This study aims to clarify whether factors associated with
restenosis after EVT in TASC II class D lesions overlap with
those in TASC II classes A to C lesions.
Methods
Study Design. This study is a subanalysis of REAL-FP
(Retrospective Multicenter Analysis for Femoropopliteal
Stenting), a nonrandomized multicenter registry study
approved by the institutional review boards at all 13 partici-
pating cardiovascular and vascular institutions in Japan
(University Hospital Medical Information NetworkdClinical
Trials Registry no. UMIN000010986).
Patients. During the study period, 14,682 patients under-
went EVT, of whom 4,697 had FP lesions treated with a
provisional stenting strategy. The following exclusion cri-
teria were then applied: 1) restenotic lesions (n ¼ 1,487);
2) history of endovascular or surgical revascularization (n ¼
164); 3) acute onset limb ischemia (n ¼ 128); 4) persistent
sciatic artery (n ¼ 2); 5) cystic adventitial disease (n ¼ 2);
6) popliteal artery entrapment syndrome (n ¼ 1); 7) femoral
access closure device-related occlusion (n ¼ 1); or 8) post-
amputation (n ¼ 1). Of the remaining 2,911 patients who
underwent EVT of an FP lesion, 5.2% (152) failed because
of: 1) failure of guidewire passage (n ¼ 124); 2) failure of
balloon catheter passage (n ¼ 9); or 3) procedure discon-
tinuation secondary to complication (n ¼ 19). Finally, 3,471
limbs in 2,759 consecutive patients who underwent EVT forde novo atherosclerotic FP lesions were enrolled from
January 1, 2004 to December 31, 2011. In all participating
centers in this study, FP disease was deﬁned as obstruction of
the femoral and popliteal arteries by atherosclerosis. In the
current study, we excluded cases with missing data on
baseline characteristics of interest. Consequently, a total of
2,400 limbs in 1,889 patients were ﬁnally included.
Interventional procedure. The indication and strategy for
the EVT procedure were decided by consensus among
consulting vascular specialists, including vascular surgeons
and interventional radiologists, based on ﬁndings on a
computed tomography or duplex ultrasound prior to diag-
nostic angiography of the lower limb. The indication for
revascularization included symptomatic patients, with >50%
diameter FP stenosis determined by angiography and mean
pressure gradient >10 mm Hg determined by a 4-F diag-
nostic catheter. The EVT approach and stent selection were
decided by the operators based on anatomical features. The
contralateral approach was the most commonly used for
access. After a 6-F sheath inser-
tion, either a 0.035- or a 0.014-
inch wire was advanced across
the lesion; unfractionated hepa-
rin (5,000 units) was adminis-
tered. Intravascular ultrasound
(IVUS) was often used, albeit not
on a regular basis and at the op-
erator’s discretion, to conﬁrm wire
passage and to assess vessel
diameter to decide optimal
balloon and stent size. A 5-mm-
diameter balloon was most fre-
quently used at nominal pressure
for 1 min in almost every case. A
nitinol stent was implanted in patients presenting with a
residual systolic pressure gradient >10 mm Hg, residual
stenosis >30%, and/or ﬂow-limiting dissection following
balloon dilation in accordance with the latest guidelines.
Self-expanding stents with diameters 1 to 2 mm larger than
the reference diameter were used. When multiple stents
were implanted, the overlap was 10 mm or longer. Provi-
sional stenting was conducted with self-expanding nitinol
stents chosen at the physicians’ discretion: Smart (Cordis,
Miami Lakes, Florida); Luminexx (BARD, Murray Hill,
New Jersey); Zilver (Cook Medical, Bloomington, Indiana);
or Misago (Terumo, Tokyo, Japan). Dual antiplatelet
therapy (aspirin 100 mg/day with cilostazol 200 mg/day or
ticlopidine 200 mg/day or clopidogrel 75 mg/day) was
started at least 1 week prior to EVT and continued until the
end of follow-up.
Follow-up protocol and study outcomes. The clinical eval-
uation, including symptom changes, ankle-brachial index,
and lesion patency assessed by duplex ultrasound, was per-
formed at baseline, 24 h, 1 month, and at every 3 months after
Inter-Society Consensus
Table 1. Baseline Characteristics of the Study Population
Overall
TASC II
Classes A to C
TASC II
Class D p Value
Patient characteristics (n ¼ 1,889) (n ¼ 1,356) (n ¼ 553)
Male 1,305 (69) 954 (70) 351 (66) 0.060
Age, yrs 73  9 72  10 74  9 <0.001
80 473 (25) 320 (23) 153 (29) 0.025
Nonambulatory status 352 (19) 223 (16) 129 (24) <0.001
Diabetes mellitus 1,170 (62) 854 (63) 316 (59) 0.141
Hypertension 1,585 (84) 1141 (84) 444 (83) 0.676
Hyperlipidemia 936 (50) 687 (51) 249 (47) 0.125
Renal insufﬁciency 709 (38) 531 (39) 178 (33) 0.020
Current smoking 490 (26) 349 (26) 141 (26) 0.771
Chronic heart failure 234 (12) 159 (12) 75 (14) 0.163
Aspirin use 1,603 (85) 1,153 (85) 450 (84) 0.775
Thienopyridine use 948 (50) 690 (51) 258 (48) 0.357
Cilostazol use 882 (47) 584 (43) 298 (56) <0.001
Limb characteristics (n ¼ 2,400) (n ¼ 1,720) (n ¼ 680)
Critical limb ischemia 847 (35) 588 (34) 259 (38) 0.072
C-reactive protein, mg/dl 1.2  2.9 1.1  2.8 1.4  3.1 0.015
3 mg/dl 266 (11) 168 (10) 98 (14) 0.001
Reference diameter, mm 5.2  1.0 5.2  1.0 5.3  0.9 0.021
<5 mm 658 (27) 503 (29) 155 (23) 0.001
Arterial calciﬁcation 1,416 (59) 974 (57) 442 (65) <0.001
Chronic total occlusion 1,117 (47) 581 (34) 536 (79) <0.001
Stent use 1,811 (75) 1,181 (69) 630 (93) <0.001
IVUS use 590 (25) 395 (23) 195 (29) 0.004
Aorto-iliac lesion 423 (18) 284 (17) 139 (20) 0.024
Poor below-the-knee runoff 1,095 (46) 761 (44) 334 (49) 0.033
Values are n (%) or mean  SD. P values between TASC II classes A to C and class D were given by
the unpaired t test for continuous variables and by the Fisher exact test for dichotomous variables.
IVUS ¼ intravascular ultrasound; TASC ¼ Trans-Atlantic Inter-Society Consensus.
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794the procedure. Reintervention was performed only when
indicated clinically by symptom recurrence. The primary
outcomemeasure was primary patency deﬁned as peak systolic
velocity ratio <2.4 assessed by duplex ultrasound (12).
Statistical analysis. Data are shown as mean  SD for
continuous variables or as percentage for dichotomous vari-
ables, unless otherwise mentioned. Between-group differ-
ences were evaluated by the unpaired t test and the Fisher
exact test for continuous and dichotomous variables, res-
pectively. Primary patency was estimated by the Kaplan-
Meier method, and the difference among groups was assessed
by the log-rank test. The association between baseline char-
acteristics with the outcome was assessed by the Cox pro-
portional regression model. Hazard ratios (HRs) are reported
with their 95% conﬁdence intervals (CIs). The inﬂuence of
the TASC II classiﬁcation on the association between base-
line characteristics and outcome was evaluated by interaction
effects. A p value less than 0.05 was considered statistically
signiﬁcant. Statistical analyses were performed by use of IBM
SPSS Statistics (version 19, IBM, Armonk, New York).
Results
Baseline patient characteristics in TASC II classes A to C
versus class D lesions. Baseline characteristics are shown in
Table 1. The mean age was 73 9 years and 69% of patients
were male. The prevalence of diabetes mellitus and renal
insufﬁciency was 62% (n ¼ 1,170) and 38% (n ¼ 709),
respectively. Thirty-ﬁve percent of limbs presented with
critical limb ischemia (CLI). TASC II class D lesions were
observed in 28% (n ¼ 680) of the cases. Compared with the
TASC II classes A to C group, the TASC II class D group
had a higher prevalence of advanced age (>80 years) (29%
vs. 23%, p ¼ 0.025), nonambulatory status (24% vs. 16%,
p < 0.001), elevated C-reactive protein levels (>3 mg/dl)
(14% vs. 10%, p ¼ 0.015), arterial calciﬁcation (65% vs.
57%, p < 0.001), chronic total occlusion (CTO) (79% vs.
34%, p < 0.001), stent use (69% vs. 93%, p < 0.001), IVUS
use (29% vs. 23%, p ¼ 0.004), aorto-iliac lesion (20%
vs. 17%, p ¼ 0.024), poor below-the-knee (BTK) runoff
(49% vs. 44%, p ¼ 0.033), and cilostazol use (56% vs. 43%,
p < 0.001). Renal insufﬁciency and a small reference
diameter (<5 mm) was more frequently observed in TASC
II classes A to C lesions (p ¼ 0.020 and 0.021, respectively).
Primary patency in TASC II classes A to C versus class D
lesions. Figure 1 shows the comparison of primary patency
between TASC II classes A to C lesions and class D lesions
after EVT based on a provisional stenting strategy. The
primary patency was 80% in the TASC II classes A to C
group versus 69% in TASC II class D group at 1 year, 62%
versus 48% at 3 years, and 49% versus 34% at 5 years,
consistently demonstrating higher rates of primary patency
in the TASC II classes A to C group up to 5 years after
provisional stenting-based EVT.Association of baseline characteristics with loss of primary
patency in TASC II classes A to C versus class D. Table 2
shows the association between baseline characteristics and
restenosis in TASC II classes A to C and class D. Inter-
action analysis demonstrated that female sex, nonambulatory
status, renal insufﬁciency, and IVUS use had a signiﬁcantly
different unadjusted hazard ratio for restenosis between
TASC II classes A to C and class D (all p for interaction
<0.05). Figures 2 to 5 show the primary patency rate among
subgroups stratiﬁed by these baseline characteristics as well
as the TASC II classiﬁcation. Female sex was associated
with an increased restenosis risk in the TASC II class D but
not the classes A to C group (Fig. 2). On the other hand,
nonambulatory status, renal insufﬁciency, and nonuse of
IVUS was associated with an increased restenosis risk in the
TASC II classes A to C group, but not in the TASC II class
D group (Figs. 3 to 5).
These ﬁndings indicate that sex, ambulatory status, renal
insufﬁciency, and IVUS use had different impacts on
restenosis between TASC II classes A to C and class D. We
therefore performed multivariate analysis, in which the
Figure 1. Comparison of Primary Patency Between TASC II Classes A to C
and Class D Lesions After Endovascular Therapy Based on a Provisional
Stenting Strategy
Primary patency was estimated by the Kaplan-Meier method. Primary patency
was 80% in the TASC (Trans-Atlantic Inter-Society Consensus) II classes A to C
group versus 69% in the TASC II class D group at 1 year, 62% versus 48% at 3
years, and 49% versus 34% at 5 years, respectively, demonstrating consistently
higher rate of primary patency in the TASC II classes A to C group up to 5 years
after endovascular therapy based on provisional stenting strategy.
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795impact of these 4 variables was stratiﬁed according to TASC
II classiﬁcation, whereas other baseline characteristics were
treated as having a common impact across TASC II classes.Table 2. Association of Baseline Characteristics With Restenosis in TASC II Cla
No. of Events / No. at Risk (Yes vs. No)
in TASC II Classes A to C in TASC II Class D
Female 147/514 vs. 318/1,206 109/236 vs. 140/444
Age 80 yrs 93/401 vs. 372/1,319 60/186 vs. 189/494
Nonambulatory status 76/287 vs. 389/1,433 46/157 vs. 203/523
Diabetes mellitus 323/1,096 vs. 142/624 158/408 vs. 91/272
Hypertension 397/1,452 vs. 68/268 213/577 vs. 36/103
Hyperlipidemia 238/866 vs. 227/854 137/330 vs. 112/350
Renal insufﬁciency 215/704 vs. 250/1,016 71/233 vs. 178/447
Current smoking 129/442 vs. 336/1,278 69/186 vs. 180/494
Chronic heart failure 73/204 vs. 392/1,516 26/90 vs. 223/590
Critical limb ischemia 152/588 vs. 313/1,132 81/259 vs. 168/421
CRP 3 mg/dl 34/168 vs. 431/1,552 24/98 vs. 225/582
Reference diameter <5 mm 146/503 vs. 319/1,217 60/155 vs. 189/525
Arterial calciﬁcation 288/974 vs. 177/746 161/442 vs. 88/238
Chronic total occlusion 179/581 vs. 286/1,139 205/536 vs. 44/144
Stent use 307/1,181 vs. 158/539 225/630 vs. 24/50
IVUS use 81/395 vs. 384/1,325 77/195 vs. 172/485
Aorto-iliac lesion 76/284 vs. 389/1,436 48/139 vs. 201/541
Poor below-the-knee runoff 226/761 vs. 239/959 120/334 vs. 129/346
Values are n/N unless otherwise indicated.
CI ¼ conﬁdence interval; CRP ¼ C-reactive protein; HR ¼ hazard ratio; other abbreviations as in TabThe results are shown in Table 3. Female sex was an in-
dependent risk factor for restenosis in TASC II class D
(adjusted HR: 1.80, p < 0.001), but not in TASC II classes
A to C (adjusted HR: 1.11, p ¼ 0.352). On the other hand,
renal insufﬁciency was an independent risk factor for reste-
nosis in TASC II classes A to C (adjusted HR: 1.43,
p < 0.001) but not in TASC II class D (adjusted HR: 0.79,
p ¼ 0.129). Diabetes mellitus, no stent use, CTO, and poor
BTK runoff were common risk factors for restenosis for
TASC II classes A to C and class D (all p < 0.05). The
adjusted HR of IVUS use was 0.80 (p ¼ 0.114) in TASC II
class D and 0.56 (p < 0.001) in TASC II classes A to C
(p for interaction overall ¼ 0.060). Similar ﬁndings were
observed even after adjustment for the use of antiplatelet
drugs (Online Table 1). In this model, cilostazol use was
independently associated with a lower risk of restenosis, with
its adjusted HR 0.67 (p < 0.002).
Association of baseline characteristics with loss of primary
patency in claudicants versus CLI patients. We additionally
investigated the determinants of restenosis in claudicants
versus CLI patients. As shown in Online Table 2, CTO and
IVUS use had a signiﬁcantly different unadjusted hazard
ratio for restenosis between claudicants and CLI patients
(p for interaction ¼ 0.017 and 0.001, respectively). The
subsequent multivariate analysis demonstrated that CTO
was an independent risk factor for restenosis in claudicants
(adjusted HR: 1.54, p > 0.001) but not in CLI patients
(adjusted HR: 1.21, p ¼ 0.174). However, the adjusted
interaction effect was not statistically signiﬁcant (p¼ 0.0134).sses A to C Versus Class D
Unadjusted HR (95% CI) for Restenosis
Interaction Effectin TASC II Classes A to C in TASC II Class D
1.18 (0.97–1.44) 1.82 (1.42–2.34) p ¼ 0.011
1.00 (0.80–1.26) 1.16 (0.87–1.56) p ¼ 0.417
1.60 (1.25–2.05) 1.04 (0.75–1.43) p ¼ 0.041
1.32 (1.08–1.61) 1.16 (0.89–1.50) p ¼ 0.372
1.03 (0.79–1.33) 0.98 (0.69–1.39) p ¼ 0.801
0.96 (0.80–1.15) 1.07 (0.83–1.37) p ¼ 0.554
1.57 (1.31–1.89) 0.85 (0.64–1.11) p < 0.001
0.93 (0.76–1.14) 0.89 (0.67–1.17) p ¼ 0.789
1.60 (1.25–2.05) 1.06 (0.71–1.60) p ¼ 0.100
1.40 (1.15–1.70) 1.26 (0.96–1.64) p ¼ 0.572
1.17 (0.83–1.66) 0.95 (0.63–1.45) p ¼ 0.480
1.10 (0.90–1.34) 0.98 (0.73–1.31) p ¼ 0.599
1.47 (1.22–1.78) 1.16 (0.89–1.50) p ¼ 0.154
1.24 (1.03–1.49) 1.11 (0.80–1.53) p ¼ 0.573
0.76 (0.63–0.92) 0.80 (0.53–1.22) p ¼ 0.863
0.54 (0.43–0.69) 0.87 (0.66–1.14) p ¼ 0.008
1.01 (0.79–1.30) 1.05 (0.77–1.44) p ¼ 0.836
1.47 (1.22–1.76) 1.27 (0.99–1.63) p ¼ 0.336
le 1.
Figure 2. Prognostic Impact of TASC II Classiﬁcation and Female Sex
The study population was stratiﬁed into 4 groups according to TASC (Trans-
Atlantic Inter-Society Consensus) II classes A to C/class D and male/female sex.
The primary patency in each subgroup was estimated by the Kaplan-Meier
method. Female patients had a signiﬁcantly better primary patency rate than
male patients in the TASC II class D group (log-rank p < 0.001), but not in the
TASC II classes A to C group (log-rank p ¼ 0.089).
Figure 4. Prognostic Impact of TASC II Classiﬁcation and RI
The study population was stratiﬁed into 4 groups according to TASC (Trans-
Atlantic Inter-Society Consensus) II classes A to C/class D and renal insufﬁ-
ciency (RI). Cases without RI had a signiﬁcantly better primary patency rate
than those with RI in the TASC II classes A to C group (log-rank p < 0.001), but
not in the TASC II class D group (log-rank p ¼ 0.234).
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796On the other hand, although IVUS use was independently
associated with a lower risk of restenosis both in claudicants
(adjusted HR: 0.79, p ¼ 0.031) and in CLI patients (adjusted
HR: 0.38, p < 0.001), the adjusted HR was signiﬁcantly
smaller in CLI patients than in claudicants (p for in-
teraction ¼ 0.002).
The ﬁndings were unchanged when the difference in the
prognostic impact of risk factors between TASC II classes AFigure 3. Prognostic Impact of TASC II Classiﬁcation and
Ambulatory Status
The study population was stratiﬁed into 4 groups according to TASC (Trans-
Atlantic Inter-Society Consensus) II classes A to C/class D and ambulatory
status. Ambulation was associated with a signiﬁcantly better primary patency
rate than nonambulatory status in the TASC II classes A to C group (log-rank p
< 0.001), but not in the TASC II class D group (log-rank p ¼ 0.828).to C and class D and between claudicants and CLI patients
was simultaneously taken into consideration (Online
Tables 3 and 4).
Discussion
We investigated differences in restenosis determinants be-
tween TASC II classes A to C and class D lesions. TheFigure 5. Prognostic Impact of TASC II Classiﬁcation and IVUS Usage
The study population was stratiﬁed into 4 groups according to TASC (Trans-
Atlantic Inter-Society Consensus) II classes A to C/class D and intravascular
ultrasound (IVUS) use. IVUS use was associated with a signiﬁcantly better
primary patency rate than no IVUS use in the TASC II classes A to C group (log-
rank p < 0.001), but not in the TASC II class D group (log-rank p ¼ 0.300).
Table 3. Adjusted Association of Baseline Characteristics With Restenosis
Adjusted HR (95% CI) (p Value) Interaction Effect
Female p ¼ 0.003
In TASC II classes A to C 1.10 (0.90–1.35) (0.352)
In TASC II class D 1.80 (1.39–2.33) (<0.001)
Age 80 yrs 1.10 (0.91–1.32) (0.344)
Nonambulatory status p ¼ 0.193
In TASC II classes A to C 1.13 (0.85–1.49) (0.402)
In TASC II class D 0.85 (0.59–1.22) (0.370)
Diabetes mellitus 1.22 (1.04–1.44) (0.015)
Hypertension 1.00 (0.80–1.23) (0.966)
Hyperlipidemia 1.01 (0.86–1.17) (0.928)
Renal insufﬁciency p ¼ 0.001
In TASC II classes A to C 1.43 (1.18–1.74) (<0.001)
In TASC II class D 0.79 (0.59–1.07) (0.129)
Current smoking 1.03 (0.87–1.23) (0.705)
Chronic heart failure 1.20 (0.96–1.51) (0.104)
Critical limb ischemia 1.10 (0.91-1.33) (0.311)
CRP 80 yrs 0.89 (0.67–1.18) (0.422)
Reference diameter <5 mm 1.07 (0.90–1.27) (0.438)
Arterial calciﬁcation 1.16 (0.99–1.36) (0.070)
Chronic total occlusion 1.42 (1.19–1.68) (<0.001)
Stent use 0.81 (0.67–0.98) (0.027)
IVUS use p ¼ 0.060
In TASC II classes A to C 0.56 (0.44–0.73) (<0.001)
In TASC II class D 0.80 (0.61–1.06) (0.114)
Aorto-iliac lesion 1.09 (0.90–1.33) (0.387)
Poor below-the-knee runoff 1.23 (1.05–1.44) (0.009)
TASC II class D 2.25 (1.64–3.07) (<0.001)
Abbreviations as in Tables 1 and 2.
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797incidence of restenosis was higher in TASC II class D than
in classes A to C lesions. Common restenosis determinants
for TASC II classes A to C and class D lesions included
diabetes mellitus, no stent usage, CTO, and poor BTK
runoff. On the other hand, female sex was a restenosis
determinant in TASC II class D lesions only, and renal
insufﬁciency was a determinant in TASC II classes A to C
lesions only (p for interaction ¼ 0.001 and 0.003, respec-
tively). As for IVUS use, the overall interaction effect on
patency did not achieve statistical signiﬁcance because of a
lack of statistical signiﬁcance for TASC II class D lesions
(p for interaction overall ¼ 0.060).
In FP disease, better mid- and long-term outcomes sec-
ondary to device improvement contributed to the guideline
update favoring increased EVT use (5). Despite being a
retrospective investigation, the positive results for stent
treatment are consistent with its more recent use as main-
stream therapeutic strategy (Table 3). Furthermore, the
supplemental analysis (Online Table 1) showed that cil-
ostazol use was associated with a lower risk of restenosis,
which was consistent with previous studies reporting a
favorable effect of cilostazol on restenosis (13). Interestingly,the current study revealed that restenosis risk factors differed
between TASC II classes A to C and class D lesions.
The current study revealed that female sex was a risk
factor for restenosis only in TASC II class D lesions,
whereas renal failure was a risk factor in TASC II classes A
to C but not class D lesions. This result appears relevant to
deciding treatment strategy in the clinical setting. Accu-
mulating evidence has demonstrated that female patients
have poorer outcomes in terms of cardiovascular death,
myocardial infarction, stroke, patency after bypass surgery,
and wound infection (14–19). Although the true mecha-
nisms remain unknown, it might be because female patients
not only have a relatively small vessel diameter but also are
more likely to suffer from a proinﬂammatory state. Severer
arterial lesions, that is, TASC II class D lesions, might be
more subject to these potential risks in female patients. The
treatment strategy for TASC II class D FP lesions in female
patients should be reconsidered.
In contrast, renal insufﬁciency was only a restenosis
determinant in TASC II classes A to C lesions, and not in
TASC II class D lesions. Renal insufﬁciency has been re-
ported to affect the vascular lesion itself, by, for instance,
promoting calciﬁcation and progression to BTK (20). In this
study, TASC II classes A to C lesions had better primary
patency than class D lesions did. One can posit that when
disease progresses to the more severe TASC II class D, renal
insufﬁciency has no affect as a restenosis factor because
overall outcomes become poor; in contrast, renal insufﬁ-
ciency has an impact on classes A to C lesions because of
their lower restenosis rate.
Finally, the use of IVUS appears to correlate well with
prognosis in at least TASC II classes A to C lesions. IVUS
use has been associated with better prognosis in the coronary
artery ﬁeld by guiding implantation position and selection
of an appropriate stent diameter to vessel diameter. IVUS
ﬁndings regarding the presence or absence of an edge dis-
section affected long-term patency. In the coronary artery
ﬁeld, minimizing stent underexpansion and maximizing
lesion area coverage with IVUS guidance has improved
outcomes (21,22). We found in TASC II class D FP lesions,
the association of IVUS use was not statistically signiﬁcant
(p for interaction: 0.060). Although the reason for the lack
of statistical signiﬁcance in TASC II class D lesions is un-
clear, one might posit that the longer calciﬁed TASC II class
D lesions produce a shadow that precludes deriving the full
beneﬁt from IVUS use; also, some of the cases could not be
properly evaluated. On the other hand, TASC II classes A
to C had better primary patency results than did TASC II
class D lesions. Therefore, appropriate acute results with
IVUS guidance may have more impact on loss of patency.
Stent use reduced restenosis rates in TASC II classes A to C
lesions, and IVUS guidance during stent implantation could
further potentiate this advantage by providing an assessment
of lesion length, thus ensuring complete coverage. This
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798study suggests that using similar strategies in the FP territory
to those for coronary arteries may be important, at least in
TASC II classes A to C lesions.
These associations were still observed even after adjust-
ment for antiplatelet drugs (Online Table 1), and after a
simultaneous consideration of the difference in the prog-
nostic affect between claudicants and CLI patients (Online
Table 4).
Study limitations. Despite being large-scale, this study was
not prospective. There could be bias concerning treatment
strategy among institutions: particularly in those where EVT
was selected or ﬁrst-generation nitinol stents were used.
Drug-eluting stents and drug-eluting balloons, which are
regularly used in recent clinical settings, were not used. IVUS
use was not regularly or consistently used to properly evaluate
appropriateness of stent selection. However, there has not
been a similar study thus far, and the results are relevant to
the treatment strategy choices in the clinical setting.
Conclusions
For de novo FP lesions, diabetes, no stent use, CTO, and
poor BTK runoff were shared restenosis predictors between
TASC II classes A to C and class D FP lesions, whereas
renal failure was a predictor in TASC II classes A to C
lesions and female sex in TASC II class D lesions.
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